OA10842A - Methods and compositions for protective and therapeutic genetic immunization - Google Patents
Methods and compositions for protective and therapeutic genetic immunization Download PDFInfo
- Publication number
- OA10842A OA10842A OA9800147A OA9800147A OA10842A OA 10842 A OA10842 A OA 10842A OA 9800147 A OA9800147 A OA 9800147A OA 9800147 A OA9800147 A OA 9800147A OA 10842 A OA10842 A OA 10842A
- Authority
- OA
- OAPI
- Prior art keywords
- virus
- cells
- cell
- host
- class
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 88
- 230000002068 genetic effect Effects 0.000 title claims abstract description 64
- 239000000203 mixture Substances 0.000 title claims abstract description 23
- 238000002649 immunization Methods 0.000 title abstract description 57
- 230000003053 immunization Effects 0.000 title abstract description 57
- 230000001681 protective effect Effects 0.000 title abstract description 10
- 230000001225 therapeutic effect Effects 0.000 title abstract description 9
- 241000700605 Viruses Species 0.000 claims abstract description 314
- 210000004027 cell Anatomy 0.000 claims abstract description 212
- 230000028993 immune response Effects 0.000 claims abstract description 89
- 210000005210 lymphoid organ Anatomy 0.000 claims abstract description 64
- 210000004443 dendritic cell Anatomy 0.000 claims abstract description 48
- 208000036142 Viral infection Diseases 0.000 claims abstract description 25
- 230000014509 gene expression Effects 0.000 claims abstract description 25
- 238000010361 transduction Methods 0.000 claims abstract description 21
- 230000026683 transduction Effects 0.000 claims abstract description 21
- 230000009385 viral infection Effects 0.000 claims abstract description 19
- 241001465754 Metazoa Species 0.000 claims abstract description 13
- 230000002463 transducing effect Effects 0.000 claims abstract description 6
- 239000000427 antigen Substances 0.000 claims description 93
- 108091007433 antigens Proteins 0.000 claims description 93
- 102000036639 antigens Human genes 0.000 claims description 93
- 206010028980 Neoplasm Diseases 0.000 claims description 54
- 108010061833 Integrases Proteins 0.000 claims description 49
- 108090000623 proteins and genes Proteins 0.000 claims description 42
- 102100034343 Integrase Human genes 0.000 claims description 40
- 108090000695 Cytokines Proteins 0.000 claims description 37
- 102000004127 Cytokines Human genes 0.000 claims description 32
- 241001430294 unidentified retrovirus Species 0.000 claims description 23
- 102000004169 proteins and genes Human genes 0.000 claims description 19
- 230000004044 response Effects 0.000 claims description 19
- 230000002950 deficient Effects 0.000 claims description 18
- 230000035772 mutation Effects 0.000 claims description 16
- 238000001727 in vivo Methods 0.000 claims description 12
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 11
- 108010065805 Interleukin-12 Proteins 0.000 claims description 8
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 8
- 108090000978 Interleukin-4 Proteins 0.000 claims description 7
- 241000701806 Human papillomavirus Species 0.000 claims description 6
- 108010002350 Interleukin-2 Proteins 0.000 claims description 5
- 241000713666 Lentivirus Species 0.000 claims description 4
- 230000005867 T cell response Effects 0.000 claims description 4
- 102000019034 Chemokines Human genes 0.000 claims description 3
- 108010012236 Chemokines Proteins 0.000 claims description 3
- 230000004568 DNA-binding Effects 0.000 claims description 3
- 208000031886 HIV Infections Diseases 0.000 claims description 3
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 claims description 3
- 108010002352 Interleukin-1 Proteins 0.000 claims description 3
- 108090000172 Interleukin-15 Proteins 0.000 claims description 3
- 101800003050 Interleukin-16 Proteins 0.000 claims description 3
- 108010002386 Interleukin-3 Proteins 0.000 claims description 3
- 108010002586 Interleukin-7 Proteins 0.000 claims description 3
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 3
- 108700004026 gag Genes Proteins 0.000 claims description 3
- 101150098622 gag gene Proteins 0.000 claims description 3
- 101710091881 GTPase HRas Proteins 0.000 claims description 2
- 102100029974 GTPase HRas Human genes 0.000 claims description 2
- 206010038997 Retroviral infections Diseases 0.000 claims description 2
- 241000287219 Serinus canaria Species 0.000 claims description 2
- SGPGESCZOCHFCL-UHFFFAOYSA-N Tilisolol hydrochloride Chemical compound [Cl-].C1=CC=C2C(=O)N(C)C=C(OCC(O)C[NH2+]C(C)(C)C)C2=C1 SGPGESCZOCHFCL-UHFFFAOYSA-N 0.000 claims 8
- 101150013359 E7 gene Proteins 0.000 claims 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 2
- 101000959820 Homo sapiens Interferon alpha-1/13 Proteins 0.000 claims 2
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims 2
- 108090001005 Interleukin-6 Proteins 0.000 claims 2
- 102000001327 Chemokine CCL5 Human genes 0.000 claims 1
- 108010055166 Chemokine CCL5 Proteins 0.000 claims 1
- 101000584633 Homo sapiens GTPase HRas Proteins 0.000 claims 1
- 101000815628 Homo sapiens Regulatory-associated protein of mTOR Proteins 0.000 claims 1
- 101000652747 Homo sapiens Target of rapamycin complex 2 subunit MAPKAP1 Proteins 0.000 claims 1
- 101000648491 Homo sapiens Transportin-1 Proteins 0.000 claims 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 claims 1
- 208000005074 Retroviridae Infections Diseases 0.000 claims 1
- 102100028748 Transportin-1 Human genes 0.000 claims 1
- 230000036755 cellular response Effects 0.000 claims 1
- 102000043600 human HRAS Human genes 0.000 claims 1
- 230000010076 replication Effects 0.000 claims 1
- 230000002238 attenuated effect Effects 0.000 abstract description 78
- 230000003612 virological effect Effects 0.000 abstract description 56
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 31
- 201000010099 disease Diseases 0.000 abstract description 30
- 239000002245 particle Substances 0.000 abstract description 29
- 230000001717 pathogenic effect Effects 0.000 abstract description 13
- 230000036039 immunity Effects 0.000 abstract description 12
- 238000011282 treatment Methods 0.000 abstract description 11
- 210000000987 immune system Anatomy 0.000 abstract description 10
- 241000282412 Homo Species 0.000 abstract description 9
- 230000007416 antiviral immune response Effects 0.000 abstract description 8
- 230000005860 defense response to virus Effects 0.000 abstract description 6
- 208000015181 infectious disease Diseases 0.000 description 60
- 108020004414 DNA Proteins 0.000 description 52
- 229960005486 vaccine Drugs 0.000 description 21
- 241000725303 Human immunodeficiency virus Species 0.000 description 19
- 238000002347 injection Methods 0.000 description 17
- 239000007924 injection Substances 0.000 description 17
- 210000000612 antigen-presenting cell Anatomy 0.000 description 16
- 210000001744 T-lymphocyte Anatomy 0.000 description 15
- 210000004881 tumor cell Anatomy 0.000 description 14
- 210000002540 macrophage Anatomy 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 13
- 210000000056 organ Anatomy 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 11
- 230000002458 infectious effect Effects 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- 241000700618 Vaccinia virus Species 0.000 description 10
- 210000004698 lymphocyte Anatomy 0.000 description 10
- 230000007918 pathogenicity Effects 0.000 description 10
- 208000030507 AIDS Diseases 0.000 description 9
- 210000002865 immune cell Anatomy 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 8
- 241001529936 Murinae Species 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 8
- 210000002950 fibroblast Anatomy 0.000 description 8
- 230000006698 induction Effects 0.000 description 8
- 210000003071 memory t lymphocyte Anatomy 0.000 description 8
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 8
- 241000282693 Cercopithecidae Species 0.000 description 7
- 108010067390 Viral Proteins Proteins 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- 238000002255 vaccination Methods 0.000 description 7
- 206010046865 Vaccinia virus infection Diseases 0.000 description 6
- 239000002502 liposome Substances 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 210000002741 palatine tonsil Anatomy 0.000 description 6
- 208000007089 vaccinia Diseases 0.000 description 6
- 201000009030 Carcinoma Diseases 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 208000032839 leukemia Diseases 0.000 description 5
- 210000001165 lymph node Anatomy 0.000 description 5
- 238000010172 mouse model Methods 0.000 description 5
- 210000005259 peripheral blood Anatomy 0.000 description 5
- 239000011886 peripheral blood Substances 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 229940031626 subunit vaccine Drugs 0.000 description 5
- 239000000277 virosome Substances 0.000 description 5
- 241000713800 Feline immunodeficiency virus Species 0.000 description 4
- 241000282553 Macaca Species 0.000 description 4
- 241001631646 Papillomaviridae Species 0.000 description 4
- 101710177166 Phosphoprotein Proteins 0.000 description 4
- 241000714223 Rauscher murine leukemia virus Species 0.000 description 4
- 206010058874 Viraemia Diseases 0.000 description 4
- 108020005202 Viral DNA Proteins 0.000 description 4
- 206010022000 influenza Diseases 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 241001529453 unidentified herpesvirus Species 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- 210000002845 virion Anatomy 0.000 description 4
- 230000001018 virulence Effects 0.000 description 4
- 101710205625 Capsid protein p24 Proteins 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 241000714165 Feline leukemia virus Species 0.000 description 3
- -1 GM-CSF Proteins 0.000 description 3
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 3
- 208000007766 Kaposi sarcoma Diseases 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- 101710149279 Small delta antigen Proteins 0.000 description 3
- 230000024932 T cell mediated immunity Effects 0.000 description 3
- 102100022563 Tubulin polymerization-promoting protein Human genes 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 230000000981 bystander Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 241001493065 dsRNA viruses Species 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000028996 humoral immune response Effects 0.000 description 3
- 230000037451 immune surveillance Effects 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000005923 long-lasting effect Effects 0.000 description 3
- 210000003563 lymphoid tissue Anatomy 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000002085 persistent effect Effects 0.000 description 3
- 230000003362 replicative effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000001177 retroviral effect Effects 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 238000011830 transgenic mouse model Methods 0.000 description 3
- 230000010415 tropism Effects 0.000 description 3
- 230000005740 tumor formation Effects 0.000 description 3
- 229960004854 viral vaccine Drugs 0.000 description 3
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 2
- 241000714266 Bovine leukemia virus Species 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 208000011691 Burkitt lymphomas Diseases 0.000 description 2
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 208000003322 Coinfection Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000282324 Felis Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 2
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000043129 MHC class I family Human genes 0.000 description 2
- 108091054437 MHC class I family Proteins 0.000 description 2
- 206010064912 Malignant transformation Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 108010021466 Mutant Proteins Proteins 0.000 description 2
- 102000008300 Mutant Proteins Human genes 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- 208000035415 Reinfection Diseases 0.000 description 2
- MJNIWUJSIGSWKK-UHFFFAOYSA-N Riboflavine 2',3',4',5'-tetrabutanoate Chemical compound CCCC(=O)OCC(OC(=O)CCC)C(OC(=O)CCC)C(OC(=O)CCC)CN1C2=CC(C)=C(C)C=C2N=C2C1=NC(=O)NC2=O MJNIWUJSIGSWKK-UHFFFAOYSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 241000713311 Simian immunodeficiency virus Species 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 201000006966 adult T-cell leukemia Diseases 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 230000005975 antitumor immune response Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 238000001815 biotherapy Methods 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 210000000234 capsid Anatomy 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000001010 compromised effect Effects 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 210000004700 fetal blood Anatomy 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 210000001821 langerhans cell Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000036212 malign transformation Effects 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000004296 naive t lymphocyte Anatomy 0.000 description 2
- 108700004028 nef Genes Proteins 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 108700026215 vpr Genes Proteins 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 description 1
- 208000031295 Animal disease Diseases 0.000 description 1
- 101710145634 Antigen 1 Proteins 0.000 description 1
- 244000125300 Argania sideroxylon Species 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 101100275473 Caenorhabditis elegans ctc-3 gene Proteins 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 1
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- XXAXVMUWHZHZMJ-UHFFFAOYSA-N Chymopapain Chemical compound OC1=CC(S(O)(=O)=O)=CC(S(O)(=O)=O)=C1O XXAXVMUWHZHZMJ-UHFFFAOYSA-N 0.000 description 1
- 108090001069 Chymopapain Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 108010031111 EBV-encoded nuclear antigen 1 Proteins 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 208000000666 Fowlpox Diseases 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 1
- 101001078143 Homo sapiens Integrin alpha-IIb Proteins 0.000 description 1
- 241000714259 Human T-lymphotropic virus 2 Species 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 102100025306 Integrin alpha-IIb Human genes 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 108010076039 Polyproteins Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 101710149136 Protein Vpr Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 241001068295 Replication defective viruses Species 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 102000000505 Ribonucleotide Reductases Human genes 0.000 description 1
- 108010041388 Ribonucleotide Reductases Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 101800001690 Transmembrane protein gp41 Proteins 0.000 description 1
- 206010044696 Tropical spastic paresis Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000014102 antigen processing and presentation of exogenous peptide antigen via MHC class I Effects 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 210000000780 bap Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000000285 follicular dendritic cell Anatomy 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000009851 immunogenic response Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 244000000056 intracellular parasite Species 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 101710130522 mRNA export factor Proteins 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000004719 natural immunity Effects 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 101150023385 nef gene Proteins 0.000 description 1
- 108010062490 p27 antigen Proteins 0.000 description 1
- 208000003154 papilloma Diseases 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000011809 primate model Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001915 proofreading effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 229940124551 recombinant vaccine Drugs 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 208000017015 squamous papilloma Diseases 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 208000006961 tropical spastic paraparesis Diseases 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
- 230000007442 viral DNA synthesis Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 101150024249 vpr gene Proteins 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/19—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/34—Antigenic peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/46—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16061—Methods of inactivation or attenuation
- C12N2740/16062—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- AIDS & HIV (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60462796A | 1996-02-21 | 1996-02-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| OA10842A true OA10842A (en) | 2001-08-14 |
Family
ID=24420371
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| OA9800147A OA10842A (en) | 1996-02-21 | 1998-08-18 | Methods and compositions for protective and therapeutic genetic immunization |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP0882134B8 (enExample) |
| JP (1) | JP2000517290A (enExample) |
| AP (1) | AP964A (enExample) |
| AT (1) | ATE429505T1 (enExample) |
| AU (1) | AU726623B2 (enExample) |
| CA (1) | CA2246359A1 (enExample) |
| DE (1) | DE69739372D1 (enExample) |
| EA (2) | EA003554B1 (enExample) |
| ES (1) | ES2324745T3 (enExample) |
| NZ (1) | NZ331369A (enExample) |
| OA (1) | OA10842A (enExample) |
| WO (1) | WO1997031119A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU3210997A (en) * | 1996-05-24 | 1997-12-09 | University Of Maryland At Baltimore | Dna vaccines for eliciting a mucosal immune response |
| US5980898A (en) | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
| US6797276B1 (en) | 1996-11-14 | 2004-09-28 | The United States Of America As Represented By The Secretary Of The Army | Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response |
| US20060002949A1 (en) | 1996-11-14 | 2006-01-05 | Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. | Transcutaneous immunization without heterologous adjuvant |
| ES2279580T3 (es) * | 1997-09-15 | 2007-08-16 | Genetic Immunity, Llc | Composiciones para administrar genes a celulas de la piel que presentan antigenos. |
| CA2314683A1 (en) * | 1997-12-12 | 1999-06-24 | Luigi Naldini | Therapeutic use of lentiviral vectors |
| WO1999047146A1 (en) * | 1998-03-17 | 1999-09-23 | Julianna Lisziwiewicz | Anti-hiv combination comprising hydroxyurea, ddi, and a protease inhibitor |
| US6461616B1 (en) * | 2000-09-09 | 2002-10-08 | Akzo Nobel Nv | EIAV p26 deletion vaccine and diagnostic |
| US20070025958A1 (en) | 2000-10-27 | 2007-02-01 | Hadden John W | Vaccine immunotherapy |
| CA2950109C (en) | 2000-10-27 | 2019-02-19 | John W. Hadden | Vaccine immunotherapy for immune suppressed patients |
| US7628980B2 (en) | 2000-11-23 | 2009-12-08 | Bavarian Nordic A/S | Modified vaccinia virus ankara for the vaccination of neonates |
| US7097842B2 (en) | 2000-11-23 | 2006-08-29 | Bavarian Nordic A/S | Modified vaccinia virus ankara for the vaccination of neonates |
| US7445924B2 (en) | 2000-11-23 | 2008-11-04 | Bavarian Nordic A/S | Modified Vaccinia Ankara virus variant and cultivation method |
| DE20122302U1 (de) | 2000-11-23 | 2005-02-24 | Bavarian Nordic A/S | Variante des Modifizierten Vaccinia-Ankara-Virus |
| PT1372708E (pt) | 2001-02-13 | 2008-09-29 | Us Gov Sec Army | Vacina para imunização transcutânea |
| AU2002356690B2 (en) | 2001-12-04 | 2008-07-24 | Bavarian Nordic A/S | Flavivirus NS1 subunit vaccine |
| JP4801880B2 (ja) | 2002-04-19 | 2011-10-26 | バヴァリアン・ノルディック・アクティーゼルスカブ | 新生仔予防接種用変異ワクシニアウイルスアンカラ |
| UA85543C2 (ru) | 2002-09-05 | 2009-02-10 | Бавариан Нордик А/С | Способ культивирования первичных клеток и амплификации вирусов в условиях безсывороточной среды, композиция и ее применение, и способ лечения или вакцинации животных |
| WO2004065575A2 (en) * | 2003-01-15 | 2004-08-05 | Research Institute For Genetic And Human Therapy (Right) | Dna compositon and uses thereof |
| FR2872170B1 (fr) * | 2004-06-25 | 2006-11-10 | Centre Nat Rech Scient Cnrse | Lentivirus non interactif et non replicatif, preparation et utilisations |
| EP1797189A4 (en) * | 2004-09-02 | 2010-05-19 | Qun Chen | ENCAPSIDATION SYSTEM FOR THE PRODUCTION OF RECOMBINANT VIRUSELY PARTICLES |
| GB0526211D0 (en) * | 2005-12-22 | 2006-02-01 | Oxford Biomedica Ltd | Viral vectors |
| ES2654303T3 (es) | 2007-05-04 | 2018-02-13 | University Health Network | Inmunoterapia de IL-12 contra el cáncer |
| AU2008329741B2 (en) | 2007-11-28 | 2013-09-12 | Irx Therapeutics, Inc. | Method of increasing immunological effect |
| WO2010009465A2 (en) * | 2008-07-18 | 2010-01-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Htlv-ii vector and methods of use |
| CA3017298C (en) | 2009-05-15 | 2021-09-28 | Irx Therapeutics, Inc. | Compositions comprising primary cell-derived biologics for enhancing immune responses in patients |
| CN103097543A (zh) | 2009-12-08 | 2013-05-08 | 伊尔克斯治疗有限公司 | 逆转朗格汉斯细胞免疫抑制的方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5342774A (en) * | 1991-05-23 | 1994-08-30 | Ludwig Institute For Cancer Research | Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1 |
| JPH08509606A (ja) * | 1993-04-20 | 1996-10-15 | ロビンソン，ウィリアム エス． | 細胞内感染因子に感染した個体を処置する方法および物質 |
| US6080408A (en) * | 1994-08-22 | 2000-06-27 | Connaught Laboratories Limited | Human immunodeficiency virus type 1 nucleic acids devoid of long terminal repeats capable of encoding for non-infectious, immunogenic, retrovirus-like particles |
-
1997
- 1997-02-20 NZ NZ331369A patent/NZ331369A/en not_active IP Right Cessation
- 1997-02-20 EP EP97906764A patent/EP0882134B8/en not_active Expired - Lifetime
- 1997-02-20 JP JP09530399A patent/JP2000517290A/ja not_active Ceased
- 1997-02-20 EA EA200100302A patent/EA003554B1/ru not_active IP Right Cessation
- 1997-02-20 AT AT97906764T patent/ATE429505T1/de not_active IP Right Cessation
- 1997-02-20 AP APAP/P/1998/001320A patent/AP964A/en active
- 1997-02-20 DE DE69739372T patent/DE69739372D1/de not_active Expired - Lifetime
- 1997-02-20 WO PCT/US1997/002933 patent/WO1997031119A1/en not_active Ceased
- 1997-02-20 EA EA199800746A patent/EA002020B1/ru not_active IP Right Cessation
- 1997-02-20 AU AU21369/97A patent/AU726623B2/en not_active Ceased
- 1997-02-20 ES ES97906764T patent/ES2324745T3/es not_active Expired - Lifetime
- 1997-02-20 CA CA002246359A patent/CA2246359A1/en not_active Abandoned
-
1998
- 1998-08-18 OA OA9800147A patent/OA10842A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ATE429505T1 (de) | 2009-05-15 |
| EA199800746A1 (ru) | 1999-02-25 |
| AU726623B2 (en) | 2000-11-16 |
| DE69739372D1 (de) | 2009-06-04 |
| EP0882134B1 (en) | 2009-04-22 |
| EP0882134B8 (en) | 2009-09-02 |
| CA2246359A1 (en) | 1997-08-28 |
| ES2324745T3 (es) | 2009-08-13 |
| NZ331369A (en) | 2001-04-27 |
| WO1997031119A1 (en) | 1997-08-28 |
| EP0882134A1 (en) | 1998-12-09 |
| AU2136997A (en) | 1997-09-10 |
| AP9801320A0 (en) | 1998-09-30 |
| EA003554B1 (ru) | 2003-06-26 |
| EA200100302A1 (ru) | 2001-10-22 |
| AP964A (en) | 2001-05-11 |
| EA002020B1 (ru) | 2001-12-24 |
| JP2000517290A (ja) | 2000-12-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AP964A (en) | Methods and compositions for protective and therapeutic genetic immunisation. | |
| EP1035865B1 (en) | Hiv-1 tat, or derivatives thereof for prophylactic and therapeutic vaccination | |
| Hanke et al. | Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime | |
| Calarota et al. | Enhancement of human immunodeficiency virus type 1‐DNA vaccine potency through incorporation of T‐helper 1 molecular adjuvants | |
| Esteban et al. | Towards a new generation of vaccines: the cytokine IL-12 as an adjuvant to enhance cellular immune responses to pathogens during prime-booster vaccination regimens | |
| AGADJANYAN et al. | An HIV type 2 DNA vaccine induces cross-reactive immune responses against HIV type 2 and SIV | |
| Stahl-Hennig et al. | Replication, immunogenicity, and protective properties of live-attenuated simian immunodeficiency viruses expressing Interleukin-4 or interferon-γ | |
| KR100354562B1 (ko) | 원숭이에서 ＳＩＶｍａｃ２３９의 감염에 대한 방어를유도하는 ＡＩＤＳ ＤＮＡ 백신 | |
| Calarota et al. | Approaches for the design and evaluation of HIV-1 DNA vaccines | |
| Bozac et al. | Expression of human immunodeficiency virus type 1 tat from a replication-deficient herpes simplex type 1 vector induces antigen-specific T cell responses | |
| Cafaro et al. | Innovative approaches to develop prophylactic and therapeutic vaccines against HIV/AIDS | |
| AU1971201A (en) | Methods and compositions for protective and therapeutic genetic immunization | |
| Ikawait | Role of cell-mediated immunity in bovine leukemia virus (BLV) infection in ruminants: its implication for the vaccination strategy against retroviruses | |
| EP1144014B1 (en) | Composition and method for obtaining specific immunisation against one or more antigens using different recombinant vectors | |
| Joy et al. | Can HIV infection be prevented with a vaccine? | |
| Barry | Recombinant vector vaccines for the prevention and treatment of HIV infection | |
| Boyer et al. | Engineering DNA vaccination as an approach to HIV immune therapy | |
| WO2003048366A1 (en) | Sivmac239 immunogenic plasmids and aids dna vaccine containing the same | |
| MXPA00005325A (en) | Hiv-1 tat, or derivatives thereof for prophylactic and therapeutic vaccination |